| 2025-12-11 |
详情>>
内部人交易：
Kropotova Alexandra股份减少988.00股
|
| 2025-11-14 |
详情>>
股本变动：
变动后总股本4760.69万股
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.73美元,归母净利润3013.44万美元,同比去年增长232.69%
|
| 2025-08-29 |
股东大会：
将于2025-09-26召开股东大会
会议内容 ▼▲
- 1.To approve the potential issuance in excess of 19.99% of the Company’s outstanding Common Stock, par value $0.0001 per share (the “Common Stock”), upon the conversion of the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), at less than the “minimum price” under Nasdaq Listing Rule 5635(d), and which may deemed a “change of control” under Nasdaq Listing Rule 5635, pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock governing the Series B Preferred Stock;
2.To approve an amendment to the Company’s 2021 Omnibus Equity Incentive Plan, as amended (the “Plan”) to, among other things, (i) increase the maximum number of shares of Common Stock available to Plan participants thereunder by 24,180,000 shares to an aggregate of 31,932,466 shares, and (ii) increase the maximum number of additional shares available for issuance pursuant to the annual evergreen increase from 10,000,000 shares to 73,750,000 shares;
3.To transact such other business as may properly come before the Special Meeting or any adjournments or postponements thereof.
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-1.65美元,归母净利润-1531.1万美元,同比去年增长-23.86%
|
| 2025-07-21 |
复牌提示：
2025-07-21 10:07:11 停牌，复牌日期 2025-07-21 10:12:11
|
| 2025-06-02 |
股东大会：
将于2025-07-17召开股东大会
会议内容 ▼▲
- 1.Elect the four Class I directors listed in the accompanying proxy statement, each to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
2.Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of SAB Biotherapeutics, Inc. for the fiscal year ending December 31, 2025.
3.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益-0.56美元,归母净利润-519.68万美元,同比去年增长-3.4%
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-3.68美元,归母净利润-3410.53万美元,同比去年增长19.17%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.45美元,归母净利润-2271.06万美元,同比去年增长-17.45%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-1.34美元,归母净利润-1236.12万美元,同比去年增长13.16%
|
| 2024-05-30 |
股东大会：
将于2024-06-27召开股东大会
会议内容 ▼▲
- 1.Elect the three Class III directors listed in the accompanying proxy statement, each to serve a three-year term expiring at the 2027 annual meeting of stockholders or until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
2.Approve an amendment to the Company’s 2021 Omnibus Equity Incentive Plan (the “Plan”) to, among other things, (i) increase the maximum number of shares of common stock available to Plan participants thereunder by 3,900,000 shares to an aggregate of 5,500,000 shares, and (ii) increase the annual evergreen percentage increase as well as the maximum number of additional shares available for issuance pursuant to the annual evergreen increase.
3.Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of SAB Biotherapeutics, Inc. for the fiscal year ending December 31, 2024.
4.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2024-05-20 |
详情>>
业绩披露：
2024年一季报每股收益-0.54美元,归母净利润-502.57万美元,同比去年增长31.66%
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-7.64美元,归母净利润-4219.38万美元,同比去年增长-125.14%
|
| 2024-01-05 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2023-12-18 |
股东大会：
将于2024-01-02召开股东大会
会议内容 ▼▲
- 1.To authorize the Company’s Board, in its discretion but prior to the one-year anniversary of the date on which the proposal is approved by the Company’s stockholders at the Special Meeting, to amend our amended and restated certificate of incorporation to effect a reverse stock split of all of the outstanding shares of our Common Stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 2-for-3 to 1-for-10, with such ratio to be determined by the Board (the “Reverse Stock Split Proposal” or “Proposal 1”).
2.To transact such other business as may properly come before the Special Meeting or any adjournments thereof.
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.38美元,归母净利润-1933.7万美元,同比去年增长-77.96%
|
| 2023-10-30 |
股东大会：
将于2023-11-22召开股东大会
会议内容 ▼▲
- 1.To approve an amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock, $0.0001 par value per share (the “Common Stock”) from 490,000,000 shares to 800,000,000;
2.To approve the potential issuance in excess of 19.99% of the Company’s outstanding Common Stock upon the conversion of the Company’s Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-1 Preferred Stock”), Series A-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-2 Preferred Stock”), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-3 Preferred Stock” and, together with the Series A-1 Preferred Stock and Series A-2 Preferred Stock, the “Series A Preferred Stock”) at less than the “minimum price” under Nasdaq Listing Rule 5635(d), and which may deemed a “change of control” under Nasdaq Listing Rule 5635, pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock governing the Series A Preferred Stock;
3.To transact such other business as may properly come before the Special Meeting or any adjournments thereof.
|
| 2023-08-21 |
详情>>
业绩披露：
2023年中报每股收益-0.28美元,归母净利润-1423.47万美元,同比去年增长-275.57%
|
| 2023-05-19 |
股东大会：
将于2023-06-29召开股东大会
会议内容 ▼▲
- 1.Elect the two Class II directors listed in the accompanying proxy statement, each to serve a three-year term expiring at the 2026 annual meeting of stockholders or until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
2.Ratify the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm of SAB Biotherapeutics, Inc. for the fiscal year ending December 31, 2023.
3.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2022-05-25 |
股东大会：
将于2022-07-06召开股东大会
会议内容 ▼▲
- 1.Elect the two Class I directors listed in the accompanying proxy statement, each to serve a three-year term expiring at the 2025 annual meeting of stockholders or until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
2.Ratify the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm of SAB Biotherapeutics, Inc. for the fiscal year ending December 31, 2022.
3.Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|